Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the label’s boxed warning that thiazolidinediones (pioglitazone component of alogliptin/pioglitazone tablets) can cause or exacerbate congestive heart failure, including monitoring and use restrictions.
Category Scores
Accurate Statements
WARNING: Congestive heart failure (i.e., that alogliptin/pioglitazone tablets can cause or exacerbate congestive heart failure; related monitoring and use restrictions)
Supported by BOXED WARNING (Congestive Heart Failure) stating thiazolidinediones including pioglitazone cause or exacerbate CHF; includes monitoring after initiation/dose increases and action if CHF develops, plus restrictions such as not recommended in symptomatic heart failure and contraindication for NYHA Class III/IV at initiation.
Unsupported Statements
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The claim does not explicitly mention the label’s specific restriction/contraindication details (not recommended in symptomatic heart failure; contraindicated for initiation in established NYHA Class III/IV).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim accurately conveys the boxed warning and that monitoring and use restrictions apply; it omits only specific heart-failure severity wording that is present in the label, which slightly reduces precision but does not negate the core warning.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Specific label restrictions (symptomatic heart failure not recommended; NYHA Class III/IV initiation contraindicated) are not explicitly stated.
Suggested Improvement
Include the label’s specific restrictions/contraindication phrasing for symptomatic heart failure and NYHA Class III/IV initiation.